Date: 2014-02-28
Type of information: Fundraising
Company: Abingworth (UK)
Investors:
Amount: £225 million (€ 269.8 million)
Funding type:
Planned used:
Others: * On February 28, 2014, Abingworth, the international investment group dedicated to life sciences and healthcare, has announced the final closing of its £225m ($375m) fund, Abingworth Bioventures VI (ABV VI). ABV VI, Abingworth’s 10th life sciences fund, exceeded its target of £200 million and invests in life sciences and healthcare both in Europe and the US. The fund invests broadly across all stages of development including early and late-stage private deals, VIPEs (Venture Investments in Public Equities), venture growth and public equities. Investment size will range from £5 million to £20 million per investment in total after all rounds of financing. The majority of the funds came from existing investors.
ABV VI is expected to make 15-20 investments and has already closed on four deals:
• Avedro (US), technology for corneal crosslinking
• Avillion (UK), structured finance for late-stage drug development
• eFFECTOR (US), novel targets for therapeutics with main focus on cancer
• GenSight Biologics (France), gene therapy for ophthalmology
Asante Capital Group LLP acted as placement agent for ABV VI. King & Wood Mallesons SJ Berwin acted as legal counsel.
Therapeutic area:
